The Switzerland market ended notably lower on Thursday due to sustained selling at several counters amid concerns about a slowdown in global economic growth. Despite the downturn and an increase in Swiss unemployment, high-growth tech stocks remain an area of interest for investors seeking potential opportunities. In this environment, identifying companies with robust innovation and strong fundamentals becomes crucial for navigating market volatility effectively.
Top 10 High Growth Tech Companies In Switzerland
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| LEM Holding | 9.25% | 18.37% | ★★★★☆☆ |
| ALSO Holding | 11.99% | 23.95% | ★★★★☆☆ |
| Santhera Pharmaceuticals Holding | 22.30% | 32.48% | ★★★★★★ |
| Temenos | 7.59% | 14.32% | ★★★★☆☆ |
| Comet Holding | 21.67% | 48.51% | ★★★★★★ |
| Cicor Technologies | 7.10% | 27.73% | ★★★★☆☆ |
| SoftwareONE Holding | 8.67% | 52.28% | ★★★★★☆ |
| Basilea Pharmaceutica | 8.99% | 36.39% | ★★★★★☆ |
| Sensirion Holding | 13.96% | 104.68% | ★★★★☆☆ |
| MCH Group | 5.18% | 83.82% | ★★★★☆☆ |
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ALSO Holding AG operates as a technology services provider for the ICT industry in Switzerland, Germany, the Netherlands, Poland, and internationally with a market cap of CHF3.14 billion.
Operations: ALSO Holding AG generates revenue primarily from its Central Europe (€4.62 billion) and Northern/Eastern Europe (€5.24 billion) segments, with a negative reconciliation of -€449.34 million. The company serves the ICT industry across multiple countries, leveraging its extensive market presence to drive business operations and growth.
ALSO Holding AG reported half-year sales of €4.28 billion, down from €4.83 billion the previous year, with net income at €41.66 million compared to €52.53 million previously. Despite this, earnings are forecast to grow 24% annually, outpacing the Swiss market’s 11.7%. The company has a strong focus on R&D, investing significantly in innovation to stay competitive in the tech industry. Earnings per share also dropped from €4.24 to €3.40.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in developing products for oncology and anti-infectives, with a market cap of CHF539.99 million.
Operations: Basilea Pharmaceutica AG generates revenue primarily through the discovery, development, and commercialization of innovative pharmaceutical products, totaling CHF149.02 million. The company’s focus is on addressing medical needs in oncology and anti-infectives.
Basilea Pharmaceutica, a notable player in the biotech sector, has recently seen its revenue dip to CHF 76.29 million from CHF 84.91 million year-over-year, with net income also decreasing to CHF 20.74 million from CHF 31.84 million. Despite this, the company is forecasted to grow earnings by an impressive 36.39% annually over the next three years and expects revenue growth of around 9% per year, outpacing the Swiss market’s average of 4.4%. Basilea’s strategic focus on R&D is evident with significant investments contributing to advancements like Cresemba®’s extended indications for pediatric use and additional market exclusivity in Europe until October 2027, which triggered a milestone payment of CHF 10 million from Pfizer Inc., highlighting its commitment to innovation and long-term growth potential in high-growth tech sectors within Switzerland’s biotech landscape.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: LEM Holding SA, along with its subsidiaries, offers solutions for measuring electrical parameters across various regions including China, Japan, South Korea, India, Southeast Asia, Europe, the Middle East, Africa, NAFTA and Latin America and has a market cap of CHF1.36 billion.
Operations: LEM Holding SA generates revenue by providing solutions for measuring electrical parameters across multiple regions worldwide. The company focuses on markets including China, Japan, South Korea, India, Southeast Asia, Europe, the Middle East, Africa, NAFTA and Latin America.
LEM Holding, a prominent player in the tech sector, has experienced a notable decline in sales to CHF 80.96 million from CHF 112.34 million year-over-year, while net income also dropped to CHF 4.78 million from CHF 20.54 million. Despite these setbacks, LEM’s revenue is forecasted to grow at an impressive rate of 9.2% annually, outpacing the Swiss market’s average of 4.4%. The company’s commitment to innovation is evident with substantial R&D expenses contributing significantly towards future growth prospects and maintaining its competitive edge in the industry.
Summing It All Up
Seeking Other Investments?
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com